Development of Treatment Agents for Neurodegenerative Disorders Using Enzyme Inhibitors

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 185

Special Issue Editor

E-Mail Website
Guest Editor
College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea
Interests: monoamine oxidase inhibitors; acetylcholinesterase inhibitors; pharmaceutical biochemistry; cell wall lytic enzyme; laccase enzyme; rumen microbial metagenome; microorganism with host
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Alzheimer’s disease (AD) and Parkinson’s disease (PD) constitute major diseases among neurodegenerative disorders. Many researchers have focused on the development of therapeutic agents, including the molecular mechanisms of the diseases in detail. However, only a small amount of progress has been made due to the complex causes of those diseases. In this Special Issue, we aim to target several important enzymes such as monoamine oxidase (MAO), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-secretase 1 (BACE1). MAO catalyzes the oxidative deamination of neurotransmitter monoamines, and it is critically related to amyloid plaque formation in AD. Isoform MAO-B is expressed at high levels in the AD brain with secretases, and it is also related to PD. AChE hydrolyzes neurotransmitter acetylcholine and is also the main target in the palliative therapy of AD, being present in both central and peripheral nervous system and in muscular motor plaques. BchE, present in the brain peripheral tissues and in the serum, is up-regulated in advanced AD. BACE1 is an aspartic acid protease and it is the major β-secretase for the generation of β-amyloid in the neurons. Additionally, anti-β-amyloid aggregation, neuroprotective activities, and related inflammation can be important areas of study.

We are inviting researchers to submit manuscripts to this Special Issue on the issue of the “Development of Treatment Agents for Neurodegenerative Disorders Using Enzyme Inhibitors”. Both experimental articles and comprehensive reviews are welcome.

Prof. Dr. Hoon Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • neurodegenerative disorders
  • Alzheimer’s disease
  • Parkinson’s disease
  • monoamine oxidase
  • C-cholinesterase
  • β-secretase 1
  • β-amyloid aggregation
  • neuroprotective activity
  • inflammation
  • inhibitors

Published Papers

This special issue is now open for submission.
Back to TopTop